If you made any changes in Pure these will be visible here soon.

Research Output 1989 2019

Filter
Article
2019

Bleeding and safety outcomes in persons with haemophilia A without inhibitors: Results from a prospective non-interventional study in a real-world setting

Kruse-Jarres, R., Oldenburg, J., Santagostino, E., Shima, M., Kempton, C. L., Kessler, C. M., Lehle, M., Chebon, S., Selak Bienz, N., Asikanius, E. & Mahlangu, J., Mar 1 2019, In : Haemophilia. 25, 2, p. 213-220 8 p.

Research output: Contribution to journalArticle

Hemophilia A
Hemorrhage
Safety
Factor VIII
Therapeutics

Consensus statements on vaccination in patients with haemophilia—results from the italian haemophilia and vaccinations (Heva) project

HEVA Study Group, Santagostino, E., Riva, A., Cesaro, S., Esposito, S., Matino, D., Mazzucchelli, R. I., Molinari, A. C., Mura, R., Notarangelo, L. D., Tagliaferri, A., Di Minno, G. & Clerici, M., Jan 1 2019, In : Haemophilia. 25, 4, p. 656-667

Research output: Contribution to journalArticle

Open Access
Hemophilia A
Vaccination
Factor VIII
Appointments and Schedules
Vaccines

Consensus statements on vaccination in patients with haemophilia—results from the italian haemophilia and vaccinations (Heva) project

Santagostino, E., Riva, A., Cesaro, S., Esposito, S., Matino, D., Mazzucchelli, R. I., Molinari, A. C., Mura, R., Notarangelo, L. D., Tagliaferri, A., Di Minno, G. & Clerici, M., Apr 1 2019, In : Haemophilia.

Research output: Contribution to journalArticle

Hemophilia A
Vaccination
Factor VIII
Appointments and Schedules
Vaccines

Fixed doses of N8-GP prophylaxis maintain moderate-to-mild factor VIII levels in the majority of patients with severe hemophilia A

Chowdary, P., Carcao, M., Holme, P. A., Jiménez-Yuste, V., Lentz, S. R., Møss, J., Poulsen, L. H., Shen, C., Tosetto, A., Wheeler, A. & Santagostino, E., Jul 2019, In : Research and practice in thrombosis and haemostasis. 3, 3, p. 542-554 13 p.

Research output: Contribution to journalArticle

Factor VIII
Hemophilia A
Half-Life
von Willebrand Factor
Pharmacokinetics
Multicenter Studies
Antiviral Agents
Hemophilia A
Infection
Interferons

Immune tolerance induction with moroctocog-alpha (Refacto/Refacto AF) in a population of Italian haemophilia A patients with high-titre inhibitors: Data from REF.IT Registry

Zanon, E., Pasca, S., Pollio, B., Santagostino, E., Linari, S., Tagliaferri, A., Santoro, C., Rocino, A., Marino, R., Aru, B., Borchiellini, A., Siragusa, S. & Coppola, A., 2019, In : Haemophilia. 25, 6, p. 1003-1010

Research output: Contribution to journalArticle

Immune Tolerance
Hemophilia A
Registries
Population
recombinant factor VIII SQ

Inhibitors in haemophilia A and B: Management of bleeds, inhibitor eradication and strategies for difficult-to-treat patients

Ljung, R., Auerswald, G., Benson, G., Dolan, G., Duffy, A., Hermans, C., Jiménez-Yuste, V., Lambert, T., Morfini, M., Zupančić-Šalek, S. & Santagostino, E., 2019, In : European Journal of Haematology. 102, 2, p. 111-122

Research output: Contribution to journalArticle

Hemophilia B
Hemophilia A
Immune Tolerance
Factor IX
Factor VIII

Once-weekly prophylaxis with glycoPEGylated recombinant factor VIII (N8-GP) in severe haemophilia A: Safety and efficacy results from pathfinder 2 (randomized phase III trial)

Curry, N., Albayrak, C., Escobar, M., Andre Holme, P., Kearney, S., Klamroth, R., Misgav, M., Négrier, C., Wheeler, A., Santagostino, E., Shima, M., Landorph, A., Tønder, S. M. & Lentz, S. R., Jan 1 2019, In : Haemophilia. 25, 3, p. 373-381

Research output: Contribution to journalArticle

Open Access
Hemophilia A
Safety
Hemorrhage
Factor VIII
Random Allocation

Patient satisfaction and acceptability of an on-demand and on-prophylaxis device for factor viii delivery in patients with hemophilia A

Italian FusENGO B1831081 Study Group, Di Minno, G., Santagostino, E., Morfini, M., Ettorre, C., Cultrera, D., Baldacci, E., Russo, E. & Gallucci, C., Jan 1 2019, In : Patient Preference and Adherence. 13, p. 233-240 8 p.

Research output: Contribution to journalArticle

Open Access
prophylaxis
Hemophilia A
Patient Satisfaction
Equipment and Supplies
questionnaire

Position paper on laboratory testing for patients with haemophilia. A consensus document from SISET, AICE, SIBioC and SIPMeL

Tripodi, A., Santoro, R. C., Testa, S., Molinari, A. C., Bernardini, S., Golato, M., Lippi, G., Ageno, W. & Santagostino, E., Jan 1 2019, In : Blood Transfusion. 17, 3, p. 229-236 8 p.

Research output: Contribution to journalArticle

Recombinant factor VIII products and inhibitor development in previously untreated patients with severe haemophilia A: Combined analysis of three studies

Volkers, P., Hanschmann, K. M., Calvez, T., Chambost, H., Collins, P. W., Demiguel, V., Hart, D. P., Hay, C. R. M., Goudemand, J., Ljung, R., Palmer, B. P., Santagostino, E., van Hardeveld, E. M., van den Berg, M. & Keller-Stanislawski, B., Jan 1 2019, In : Haemophilia. 25, 3, p. 398-407

Research output: Contribution to journalArticle

Factor VIII
Hemophilia A
Isoantibodies
Cohort Studies
Therapeutics

Safety and efficacy of BAY 94-9027, an extended-half-life factor VIII, during surgery in patients with severe hemophilia A: Results of the PROTECT VIII clinical trial

Santagostino, E., Lalezari, S., Reding, M. T., Ducore, J., Ng, H. J., Poulsen, L. H., Michaels, L. A. & Linardi, C. C. G., Nov 1 2019, In : Thrombosis Research. 183, p. 13-19 7 p.

Research output: Contribution to journalArticle

Open Access
Factor VIII
Hemophilia A
Half-Life
Clinical Trials
Safety

Switching patients in the age of long-acting recombinant products?

Escobar, M., Santagostino, E., Mancuso, M. E., Coppens, M., Balasa, V., Taylor, J. A., Iorio, A. & Negrier, C., Jan 14 2019, In : Expert Review of Hematology. 12, sup1, p. 1-13 13 p.

Research output: Contribution to journalArticle

Open Access
Pharmacokinetics
Hemorrhage
Safety
Factor IX
Expert Testimony

Systematic review and analysis of efficacy of recombinant factor IX products for prophylactic treatment of hemophilia B in comparison with rIX-FP

Davis, J., Yan, S., Matsushita, T., Alberio, L., Bassett, P. & Santagostino, E., Jan 1 2019, In : Journal of Medical Economics. 22, 10, p. 1014-1021

Research output: Contribution to journalArticle

Hemophilia B
Factor IX
Half-Life
Joints
Hemorrhage

The changing face of immune tolerance induction in haemophilia A with the advent of emicizumab

Future of Immunotolerance Treatment Group, Jul 1 2019, In : Haemophilia. 25, 4, p. 676-684 9 p.

Research output: Contribution to journalArticle

Open Access
Immune Tolerance
Hemophilia A
Therapeutics
emicizumab
Prospective Studies

The effect of emicizumab prophylaxis on health-related outcomes in persons with haemophilia A with inhibitors: HAVEN 1 Study

Oldenburg, J., Mahlangu, J. N., Bujan, W., Trask, P., Callaghan, M. U., Young, G., Asikanius, E., Peyvandi, F., Santagostino, E., Kruse-Jarres, R., Negrier, C., Kessler, C., Xu, J., Windyga, J., Shima, M. & von Mackensen, S., 2019, In : Haemophilia. 25, 1, p. 33-44

Research output: Contribution to journalArticle

Hemophilia A
Health
Heme
Quality of Life
Factor VIII

Thrombin activatable fibrinolysis inhibitor pathway alterations correlate with bleeding phenotype in patients with severe hemophilia A

Semeraro, F., Mancuso, M. E., Ammollo, C. T., Dirienzo, L., Vitulli, A., Santagostino, E., Tripodi, A. & Colucci, M., Jan 1 2019, (Accepted/In press) In : Journal of Thrombosis and Haemostasis.

Research output: Contribution to journalArticle

Carboxypeptidase B2
Hemophilia A
Hemorrhage
Phenotype
Fibrin Clot Lysis Time
2018

Ageing successfully with haemophilia: A multidisciplinary programme

Boccalandro, E., Mancuso, M. E., Riva, S., Pisaniello, D. M., Ronchetti, F., Santagostino, E., Peyvandi, F., Solimeno, L. P., Mannucci, P. M. & Pasta, G., 2018, In : Haemophilia. 24, 1, p. 57-62

Research output: Contribution to journalArticle

Hemophilia A
Hemophilia B
Physical Therapists
Italy
Education

Bleeding events and safety outcomes in persons with haemophilia A with inhibitors: A prospective, multi-centre, non-interventional study

Mahlangu, J., Oldenburg, J., Callaghan, M. U., Shima, M., Santagostino, E., Moore, M., Recht, M., Garcia, C., Yang, R., Lehle, M., Macharia, H., Asikanius, E., Levy, G. G. & Kruse-Jarres, R., 2018, In : Haemophilia. 24, 6, p. 921-929

Research output: Contribution to journalArticle

Hemophilia A
Hemorrhage
Safety
Factor VIII
Hemarthrosis

Comorbidities in persons with haemophilia aged 60 years or more compared with age-matched people from the general population

Marchesini, E., Oliovecchio, E., Coppola, A., Santagostino, E., Radossi, P., Castaman, G., Valdrè, L., Santoro, C., Tagliaferri, A., Ettorre, C., Zanon, E., Barillari, G., Cantori, I., Caimi, T. M., Sottilotta, G., Iorio, A. & Mannucci, P. M., 2018, In : Haemophilia. 24, 1, p. e6-e10

Research output: Contribution to journalArticle

Defining extended half-life rFVIII-A critical review of the evidence

Mahlangu, J., Young, G., Hermans, C., Blanchette, V., Berntorp, E. & Santagostino, E., 2018, In : Haemophilia. 24, 3, p. 348-358

Research output: Contribution to journalArticle

Half-Life
Pharmacokinetics
Hemophilia A
Cross-Over Studies
Technology

Desmopressin in moderate hemophilia a patients: A treatment worth considering

Rise Consortium, Feb 28 2018, In : Haematologica. 103, 3, p. 550-557 8 p.

Research output: Contribution to journalArticle

Deamino Arginine Vasopressin
Hemophilia A
Factor VIII
Therapeutics
von Willebrand Factor

Long-term safety and efficacy of turoctocog alfa in prophylaxis and treatment of bleeding episodes in severe haemophilia A: Final results from the guardian 2 extension trial

Lentz, S. R., Janic, D., Kavakli, K., Miljic, P., Oldenburg, J., C. Ozelo, M., Santagostino, E., Suzuki, T., Zupancic Šalek, S., Korsholm, L., Matytsina, I. & Tiede, A., 2018, In : Haemophilia. 24, 6, p. e391-e394

Research output: Contribution to journalArticle

Hemophilia A
Hemorrhage
Safety
Factor VIII
Therapeutics
Hemophilia A
Outcome Assessment (Health Care)
Databases
Hemorrhage
Cohort Studies

Pharmacokinetic modelling and validation of the half-life extension needed to reduce the burden of infusions compared with standard factor VIII

Hermans, C., Mahlangu, J., Booth, J., Schütz, H., Santagostino, E., Young, G., Lee, H. Y., Steinitz-Trost, K. N., Blanchette, V. & Berntorp, E., 2018, In : Haemophilia. 24, 3, p. 376-384

Research output: Contribution to journalArticle

Factor VIII
Life Expectancy
Half-Life
Pharmacokinetics
Benchmarking

Prophylaxis re-visited: The potential impact of novel factor and non-factor therapies on prophylaxis

Carcao, M., Lambert, T., Leissinger, C., Escuriola-Ettingshausen, C., Santagostino, E. & Aledort, L., 2018, In : Haemophilia. 24, 6, p. 845-848

Research output: Contribution to journalArticle

Rate and appropriateness of polypharmacy in older patients with hemophilia compared with age-matched controls

Mannucci, P. M., Nobili, A., Marchesini, E., Oliovecchio, E., Cortesi, L., Coppola, A., Santagostino, E., Radossi, P., Castaman, G., Valdrè, L., Santoro, C., Tagliaferri, A., Ettorre, C., Zanon, E., Barillari, G., Cantori, I., Caimi, T. M., Sottilotta, G., Peyvandi, F. & Iorio, A., 2018, In : Haemophilia. 24, 5, p. 726-732

Research output: Contribution to journalArticle

Polypharmacy
Hemophilia A
Drug Interactions
Pharmaceutical Preparations
Prescriptions

Treatment Regimens with Bypassing Agents in Patients with Hemophilia A and Inhibitors: A Survey from the Italian Association of Hemophilia Centers (AICE)

Coppola, A., Franchini, M., Castaman, G., Santagostino, E., Santoro, C., Santoro, R. C., Morfini, M., Di Minno, G. & Rocino, A., 2018, In : Seminars in Thrombosis and Hemostasis. 44, 6, p. 551-560

Research output: Contribution to journalArticle

Hemophilia A
Proxy
Therapeutics
Hemorrhage
Factor VIIa
Hemophilia A
Joints
Bone Density
Bone and Bones
Hip

Usefulness of bone microarchitectural and geometric DXA-derived parameters in haemophilic patients

Ulivieri, F. M., Rebagliati, G. A. A., Piodi, L. P., Solimeno, L. P., Pasta, G., Boccalandro, E., Fasulo, M. R., Mancuso, M. E. & Santagostino, E., 2018, In : Haemophilia. 24, 6, p. 980-987 8 p.

Research output: Contribution to journalArticle

2017

Beyond stopping the bleed: Short-term episodic prophylaxis with recombinant activated factor FVII in haemophilia patients with inhibitors

Šalek, S. Z., Auerswald, G., Benson, G., Dolan, G., Duffy, A., Hermans, C., Jiménez-Yuste, V., Ljung, R., Morfini, M., Santagostino, E. & Lambert, T., Jan 1 2017, In : Blood Transfusion. 15, 1, p. 77-84 8 p.

Research output: Contribution to journalArticle

Hemophilia A
Joint Diseases
Therapeutics
Hemarthrosis
Hemorrhage

Clinical evaluation of glycoPEGylated recombinant FVIII: Efficacy and safety in severe haemophilia A

Giangrande, P., Andreeva, T., Chowdary, P., Ehrenforth, S., Hanabusa, H., Leebeek, F. W. G., Lentz, S. R., Nemes, L., Poulsen, L. H., Santagostino, E., You, C. W., Clausen, W. H. O., Jönsson, P. G., Oldenburg, J., Rothschild, C., Lambert, T., Trossaert, M., Negrier, C., Miesbach, W., Tiede, A. & 73 others, Oldenburg, J., Klamroth, R., Eichler, H., Santagostino, E., Tosetto, A., Dunsmore, K., Escobar, M., Wright, J., Gruppo, R., Guron, G. K., Kearney, S., Lasky, J., Lentz, S., Kutlar, A., Paroskie-Wheeler, A., Powell, J. S., Recht, M., Takemoto, C., Cockrell, E., Yee, D., Felgenhauer, J., Apollonsky, N., Lazarchick, J., Kulkarni, R., Knoll, C., Morales, J., Kavasch, P., Nagasubramanian, G. R., Guerrera, M., Chitlur, M., Lowe, E., Tsay, W., Shen, M. C., Zupancic-Salek, S., Kampmann, P., Poulsen, L. H., Boda, Z., Nemes, L., Leebeek, F. W. G., Meijer, K., Holme, P. A., Jiménez Yuste, V., Mingot, E. M., Zetterberg, E., Brand, B., Alberio, L., Boehlen, F., Thomson, G., Chowdary, P., Collins, P. W., Curry, N., Hampton, K., Rangarajan, S., Barnes, C., Brown, S., Dunkley, S., Castro Ozelo, M., Misgav, M., Karim, F. A., Sathar, J., Andreeva, T. A., Kavakli, K., Sasmaz, I., Albayrak, C., Fukutake, K., Matsushita, T., Hanabusa, H., Madoiwa, S., Shima, M., Fujii, T., Sato, T., Takedani, H. & Shibuya, A., 2017, In : Thrombosis and Haemostasis. 117, 2, p. 252-261 10 p.

Research output: Contribution to journalArticle

Factor VIII
Hemophilia A
Safety
Injections
Hemorrhage

Cost-effectiveness analysis of late prophylaxis vs. on-demand treatment for severe haemophilia A in Italy

Coppola, A., D'Ausilio, A., Aiello, A., Amoresano, S., Toumi, M., Mathew, P., Tagliaferri, A., Group, T. P. S., Feola, G., Molinari, A. C., Santoro, C., Rivolta, G. F., Cultrera, D. B., Gagliano, F., Zanon, E., Mancuso, M. E., Valdrè, L., Mameli, L., Banov, L., Di Minno, G. & 4 others, Quintavalle, G., Mazzucconi, M. G., Negri, N. & Santagostino, E., 2017, In : Haemophilia. 23, 3, p. 422-429 8 p.

Research output: Contribution to journalArticle

Emicizumab prophylaxis in hemophilia A with inhibitors

Oldenburg, J., Mahlangu, J. N., Kim, B., Schmitt, C., Callaghan, M. U., Young, G., Santagostino, E., Krusejarres, R., Negrier, C., Kessler, C., Valente, N., Asikanius, E., Levy, G. G., Windyga, J. & Shima, M., Aug 31 2017, In : New England Journal of Medicine. 377, 9, p. 809-818 10 p.

Research output: Contribution to journalArticle

Hemophilia A
Hemorrhage
Factor VIIIa
Factor IXa
emicizumab

European retrospective study of real-life haemophilia treatment

Berntorp, E., Dolan, G., Hay, C., Linari, S., Santagostino, E., Tosetto, A., Castaman, G., Álvarez-Román, M., Parra Lopez, R., Oldenburg, J., Albert, T., Scholz, U., Holmström, M., Schved, J. F., Trossaërt, M., Hermans, C., Boban, A., Ludlam, C. & Lethagen, S., 2017, In : Haemophilia. 23, 1, p. 105-114

Research output: Contribution to journalArticle

Hemophilia A
Retrospective Studies
Hemophilia B
Therapeutics
Blood Coagulation Factors

First report on the safety and efficacy of an extended half-life glycoPEGylated recombinant FVIII for major surgery in severe haemophilia A

Hampton, K., Chowdary, P., Dunkley, S., Ehrenforth, S., Jacobsen, L., Neff, A., Santagostino, E., Sathar, J., Takedani, H., Takemoto, C. M. & Négrier, C., 2017, In : Haemophilia. 23, 5, p. 689-696

Research output: Contribution to journalArticle

Factor VIII
Hemophilia A
Half-Life
Safety
Replacement Arthroplasties
Hemophilia B
Factor IX
Basophils
Complement Activation
Anaphylaxis

Pharmacokinetics of a novel extended half-life glycoPEGylated factor IX, nonacog beta pegol (N9-GP) in previously treated patients with haemophilia B: results from two phase 3 clinical trials

Tiede, A., Abdul-Karim, F., Carcao, M., Persson, P., Clausen, W. H. O., Kearney, S., Matsushita, T., Negrier, C., Oldenburg, J., Santagostino, E. & Young, G., Jul 1 2017, In : Haemophilia. 23, 4, p. 547-555 9 p.

Research output: Contribution to journalArticle

Hemophilia B
Phase III Clinical Trials
Factor IX
Half-Life
Pharmacokinetics

Risk Factors for the Progression from Low to High Titres in 260 Children with Severe Haemophilia A and Newly Developed Inhibitors

Mancuso, M. E., Fischer, K., Santagostino, E., Oldenburg, J., Platokouki, H., Königs, C., Ettingshausen, C. E., Rivard, G. E., Cid, A. R., Carcao, M., Ljung, R., Petrini, P., Roca, C. A. & et al., 2017, In : Thrombosis and Haemostasis. 117, 12, p. 2274-2282

Research output: Contribution to journalArticle

2016

A randomized trial of factor VIII and neutralizing antibodies in hemophilia A

Peyvandi, F., Mannucci, P. M., Garagiola, I., El-Beshlawy, A., Elalfy, M., Ramanan, V., Eshghi, P., Hanagavadi, S., Varadarajan, R., Karimi, M., Manglani, M. V., Ross, C., Young, G., Seth, T., Apte, S., Nayak, D. M., Santagostino, E., Mancuso, M. E., Sandoval Gonzalez, A. C., Mahlangu, J. N. & 27 others, Bonanad Boix, S., Cerqueira, M., Ewing, N. P., Male, C., Owaidah, T., Arellano, S. V., Kobrinsky, N. L., Majumdar, S., Perez Garrido, R., Sachdeva, A., Simpson, M., Thomas, M., Zanon, E., Antmen, B., Kavakli, K., Manco-Johnson, M. J., Martinez, M., Marzouka, E., Mazzucconi, M. G., Neme, D., Palomo Bravo, A., Paredes Aguilera, R., Prezotti, A., Schmitt, K., Wicklund, B. M., Zulfikar, B. & Rosendaal, F. R., May 26 2016, In : New England Journal of Medicine. 374, 21, p. 2054-2064 11 p.

Research output: Contribution to journalArticle

Factor VIII
Hemophilia A
Neutralizing Antibodies
Isoantibodies
Incidence

Clinical overview of Fanhdi/Alphanate (plasma-derived, VWF-containing FVIII concentrate) in immune tolerance induction in haemophilia A patients with inhibitors

Jiménez-Yuste, V., Oldenburg, J., Rangarajan, S., Kurth, M. H., Bozzo, J. & Santagostino, E., Jan 1 2016, In : Haemophilia. 22, 1, p. e71-e74

Research output: Contribution to journalArticle

Comparative pharmacokinetics of rVIII-SingleChain and octocog alfa (Advate®) in patients with severe haemophilia A

Klamroth, R., Simpson, M., von Depka-Prondzinski, M., Gill, J. C., Morfini, M., Powell, J. S., Santagostino, E., Davis, J., Huth-Kühne, A., Leissinger, C., Neumeister, P., Bensen-Kennedy, D., Feussner, A., Limsakun, T., Zhou, M., Veldman, A., St. Ledger, K., Blackman, N. & Pabinger, I., Sep 1 2016, In : Haemophilia. 22, 5, p. 730-738 9 p.

Research output: Contribution to journalArticle

Hemophilia A
Factor VIII
Pharmacokinetics
von Willebrand Factor
Patient Compliance

Daclatasvir/peginterferon lambda-1a/ribavirin in patients with chronic HCV infection and haemophilia who are treatment naïve or prior relapsers to peginterferon alfa-2a/ribavirin

Santagostino, E., Pol, S., Olveira, A., Reesink, H. W., van Erpecum, K., Bogomolov, P., Xu, D., Critelli, L., Srinivasan, S. & Cooney, E., Sep 1 2016, In : Haemophilia. 22, 5, p. 692-699 8 p.

Research output: Contribution to journalArticle

Ribavirin
Hemophilia A
Chronic Hepatitis C
Virus Diseases
Hepacivirus

Efficacy and safety of long-acting recombinant fusion protein linking factor IX with albumin in haemophilia B patients undergoing surgery

Négrier, C., Abdul Karim, F., Lepatan, L. M., Lienhart, A., López-Fernández, M. F., Mahlangu, J., Pabinger, I., Li, Y., Wolko, D., Voigt, C., Jacobs, I. & Santagostino, E., Jul 1 2016, In : Haemophilia. 22, 4, p. e259-e266

Research output: Contribution to journalArticle

Recombinant Fusion Proteins
Hemophilia B
Factor IX
Albumins
Safety

Efficacy and safety of rVIII-Singlechain: Results of a phase 1/3 multicenter clinical trial in severe hemophilia A

Mahlangu, J., Kuliczkowski, K., Karim, F. A., Stasyshyn, O., Kosinova, M. V., Lepatan, L. M., Skotnicki, A., Boggio, L. N., Klamroth, R., Oldenburg, J., Hellmann, A., Santagostino, E., Baker, R. I., Fischer, K., Gill, J. C., P'Ng, S., Chowdary, P., Escobar, M. A., Khayat, C. D., Rusen, L. & 6 others, Bensen-Kennedy, D., Blackman, N., Limsakun, T., Veldman, A., Ledger, K. S. & Pabinger, I., Aug 4 2016, In : Blood. 128, 5, p. 630-637 8 p.

Research output: Contribution to journalArticle

Factor VIII
Hemophilia A
Multicenter Studies
Clinical Trials
Hemorrhage

High serum sclerostin levels in children with haemophilia A

Giordano, P., Brunetti, G., Lassandro, G., Notarangelo, L. D., Luciani, M., Mura, R. M., Lazzareschi, I., Santagostino, E., Piacente, L., Ventura, A., Cavallo, L., Grano, M. & Faienza, M. F., Jan 1 2016, In : British Journal of Haematology. 172, 2, p. 293-295 3 p.

Research output: Contribution to journalArticle

High serum sclerostin levels in children with haemophilia A

Giordano, P., Brunetti, G., Lassandro, G., Notarangelo, L. D., Luciani, M., Mura, R. M., Lazzareschi, I., Santagostino, E., Piacente, L., Ventura, A., Cavallo, L., Grano, M. & Faienza, M. F., Jan 1 2016, In : British Journal of Haematology. 172, 2, p. 293-295 3 p.

Research output: Contribution to journalArticle

Increased inhibitor incidence in severe haemophilia A since 1990 attributable to more low titre inhibitors

van den Berg, H. M., Hashemi, S. M., Fischer, K., Petrini, P., Ljung, R., Rafowicz, A., Carcao, M., Auerswald, G., Kurnik, K., Kenet, G. & Santagostino, E., Apr 1 2016, In : Thrombosis and Haemostasis. 115, 4, p. 729-737 9 p.

Research output: Contribution to journalArticle

Hemophilia A
Incidence
Parturition
Therapeutics
Investigational Therapies
Pharmacology
cancer procoagulant
Blood Coagulation Factors
Factor VIII